Inequitable Conduct Ruling Against Synthon Upheld

Law360, New York (June 17, 2008, 12:00 AM EDT) -- A federal appeals court has rejected Synthon IP's challenge of a trial court's decision that two patents Synthon asserted against Pfizer Inc. in a case over the blockbuster blood pressure drug Norvasc are unenforceable due to inequitable conduct.

The U.S. Court of Appeals for the Federal Circuit handed down a brief decision Tuesday affirming the U.S. District Court for the Eastern District of Virginia's findings of inequitable conduct and the lower court's decision to award Pfizer attorneys' fees.

“Under these circumstances, we need not reach the...
To view the full article, register now.